Hancock Jaffe Laboratories is a medical device company developing tissue based solutions that are designed to be life sustaining or life improving for patients with cardiovascular disease, and peripheral arterial and venous disease. Co.'s two main products which it is developing are: the VenoValve®, a porcine based device to be surgically implanted in the deep venous system of the leg to treat a debilitating condition called chronic venous insufficiency; and the CoreoGraft®, a bovine based conduit to be used to revascularize the heart during coronary artery bypass graft surgeries. We show 16 historical shares outstanding datapoints in our HJLI shares outstanding history coverage, used to compute HJLI market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing HJLI market cap history over the course of time is important for investors
interested in comparing HJLI's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of HJLI versus a peer is one thing; comparing
HJLI market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like HJLI can fluctuate over the course of history.
With this page we aim to empower investors researching HJLI by allowing them to research the HJLI market cap history. |
Free HJLI Email Alerts:
Video: The Importance of Market Cap
